公开(公告)号：US20160083472A1

公开(公告)日：2016-03-24

申请号：US14686422

申请日：2015-04-14

申请人： Randolph J. Noelle ,  Li Wang ,  Thomas Broughton ,  Lorenzo F. Sempere ,  Janet Louise Lines

发明人： Randolph J. Noelle ,  Li Wang ,  Thomas Broughton ,  Lorenzo F. Sempere ,  Janet Louise Lines

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61K39/00 ,  C07K16/30 ,  A61K45/06

CPC分类号： C07K16/2827 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0005 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/57 ,  A61P35/00 ,  A61P37/00 ,  C07K7/08 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3023 ,  C07K2317/75 ,  C07K2317/76

摘要： The present invention is directed to synergic or additive therapies comprising the administration of a VISTA antagonist and a PD-1, PD-L1 or POD-L3 antagonist; or the combination of a VISTA agonist and a -1, PD-L1 or POD-L3 agonist which combinations respectively elicit an additive or synergistic effect at promoting T cell immunity or inhibiting T cell immunity, i.e., CD4, CD8 or Th1 immunity. The agonists and antagonists may be in the same or separate compositions and may be administered together or separately administered in either order.

摘要翻译： 本发明涉及包括施用VISTA拮抗剂和PD-1，PD-L1或POD-L3拮抗剂的协同或添加剂疗法; 或VISTA激动剂和-1，PD-L1或POD-L3激动剂的组合，其组合分别在促进T细胞免疫或抑制T细胞免疫（即CD4，CD8或Th1免疫）方面引起添加剂或协同效应。 激动剂和拮抗剂可以在相同或分开的组合物中，并且可以一起施用或以任何顺序分开施用。

公开(公告)号：US20180237525A9

公开(公告)日：2018-08-23

申请号：US14686422

申请日：2015-04-14

申请人： Randolph J. Noelle ,  Li Wang ,  Thomas Broughton ,  Lorenzo F. Sempere ,  Janet Louise Lines

发明人： Randolph J. Noelle ,  Li Wang ,  Thomas Broughton ,  Lorenzo F. Sempere ,  Janet Louise Lines

IPC分类号： C07K16/28 ,  C07K16/30 ,  A61K45/06 ,  A61K39/00 ,  A61K39/395

CPC分类号： C07K16/2827 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0005 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/57 ,  A61P35/00 ,  A61P37/00 ,  C07K7/08 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3023 ,  C07K2317/75 ,  C07K2317/76

摘要： The present invention is directed to synergic or additive therapies comprising the administration of a VISTA antagonist and a PD-1, PD-L1 or POD-L3 antagonist; or the combination of a VISTA agonist and a -1, PD-L1 or POD-L3 agonist which combinations respectively elicit an additive or synergistic effect at promoting T cell immunity or inhibiting T cell immunity, i.e., CD4, CD8 or Th1 immunity. The agonists and antagonists may be in the same or separate compositions and may be administered together or separately administered in either order.